PMID- 35470006 OWN - NLM STAT- MEDLINE DCOM- 20220614 LR - 20220614 IS - 1873-6963 (Electronic) IS - 0965-2299 (Linking) VI - 68 DP - 2022 Sep TI - Effectiveness and safety of electric heating moxibustion for perennial allergic rhinitis: A pilot, randomized, assessor-blind trial. PG - 102835 LID - S0965-2299(22)00037-1 [pii] LID - 10.1016/j.ctim.2022.102835 [doi] AB - BACKGROUND: The prevalence of allergic rhinitis (AR), an inflammatory disease, is gradually increasing. Studies have reported that moxibustion is effective for treating AR. Electric heating moxibustion (EM) was developed to offer adaptable heat stimulation without the generation of smoke. OBJECTIVES: The objective of this study was to examine the possibility of EM in treating perennial allergic rhinitis (PAR) and to assess the feasibility of using this technique on a larger scale by comparing EM with acupuncture (AC). DESIGN: A randomized pilot study was conducted on 40 patients with PAR. Patients were randomly assigned to one of two treatment groups: EM or AC. The primary outcome measure was the change in the total nasal symptom score (TNSS) between before and after treatment. The secondary outcome measures were the changes in the rhinoconjunctivitis quality of life questionnaire (RQLQ), nasal endoscopy index for pattern identification, pattern identification questionnaire for AR, total serum immunoglobulin E (IgE), eosinophil count, and adverse effects (AEs). RESULTS: The results showed a statistically significant improvement in mean TNSS and RQLQ scores in both groups (p < 0.05), but no significant difference between the two groups. However, mean changes in itching and sneezing TNSS were significantly higher in the AC group. There was no significant difference in total serum IgE or eosinophil count before versus after treatment, nor was there any significant difference of three pattern subgroups between the two groups in the mean TNSS change. While the AC group reported two treatment-related AEs, there were no treatment-related AEs in the EM group. CONCLUSION: This trial provides evidence that EM isa safe alternative treatment for patients with PAR. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03342105. Registered on 14 November 2017. CI - Copyright (c) 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Jo, Hyo-Rim AU - Jo HR AD - Department of Acupuncture & Moxibustion, College of Korean Medicine, Dongguk University Graduate School, Seoul, Republic of Korea. Electronic address: sunny4396@hanmail.net. FAU - Sung, Won-Suk AU - Sung WS AD - Department of Acupuncture & Moxibustion, Dongguk University Bundang Oriental Hospital, Seongnam, Republic of Korea. Electronic address: 1984sws@hanmail.net. FAU - Jung, Chan-Yung AU - Jung CY AD - Department of Acupuncture & Moxibustion, Dongguk University Ilsan Oriental Hospital, Goyang, Republic of Korea. Electronic address: yyoung81@hanmail.net. FAU - Lim, Chi-Yeon AU - Lim CY AD - Department of Biostatistics, College of Medicine, Dongguk University, Goyang, Republic of Korea. Electronic address: rachun@hanmail.net. FAU - Lee, Seung-Deok AU - Lee SD AD - Institute of Oriental Medicine, College of Korean Medicine, Dongguk University, Goyang, Republic of Korea. Electronic address: chunkman@dongguk.edu. FAU - Hong, Seung-Ug AU - Hong SU AD - Department of Ophthalmology, Otolaryngology and Dermatology, Dongguk University Ilsan Oriental Hospital, Gyeonggi-do, Republic of Korea. Electronic address: heenthsu@hanmail.net. FAU - Kim, Kyung-Ho AU - Kim KH AD - Department of Acupuncture & Moxibustion, Dongguk University Ilsan Oriental Hospital, Goyang, Republic of Korea. Electronic address: omdkkh@hanmail.net. FAU - Kim, Eun-Jung AU - Kim EJ AD - Department of Acupuncture & Moxibustion, Dongguk University Bundang Oriental Hospital, Seongnam, Republic of Korea. Electronic address: hanijjung@naver.com. LA - eng SI - ClinicalTrials.gov/NCT03342105 PT - Journal Article PT - Randomized Controlled Trial DEP - 20220422 PL - Scotland TA - Complement Ther Med JT - Complementary therapies in medicine JID - 9308777 RN - 37341-29-0 (Immunoglobulin E) SB - IM MH - Heating MH - Humans MH - Immunoglobulin E MH - *Moxibustion/adverse effects MH - Pilot Projects MH - Quality of Life MH - *Rhinitis, Allergic/therapy MH - *Rhinitis, Allergic, Perennial MH - Treatment Outcome OTO - NOTNLM OT - Allergic rhinitis OT - Electric heating moxibustion OT - Moxibustion OT - Randomized controlled trial EDAT- 2022/04/27 06:00 MHDA- 2022/06/15 06:00 CRDT- 2022/04/26 05:57 PHST- 2020/11/25 00:00 [received] PHST- 2022/04/07 00:00 [revised] PHST- 2022/04/19 00:00 [accepted] PHST- 2022/04/27 06:00 [pubmed] PHST- 2022/06/15 06:00 [medline] PHST- 2022/04/26 05:57 [entrez] AID - S0965-2299(22)00037-1 [pii] AID - 10.1016/j.ctim.2022.102835 [doi] PST - ppublish SO - Complement Ther Med. 2022 Sep;68:102835. doi: 10.1016/j.ctim.2022.102835. Epub 2022 Apr 22.